Arcede Pharma
Arcede Pharma is a company focused on developing new patent-protected drug candidates for chronic obstructive pulmonary disease (COPD) and severe asthma, aiming to improve quality of life and reduce suffering. It was founded in 2022 as a spin-out from Respiratorius, with a strategic focus on respiratory diseases and collaborations with academic and industry partners. The company operates with a virtual organizational model and aims to bring innovative treatments to market through strategic partnerships and early-stage development.
Industries
Nr. of Employees
small (1-50)
Arcede Pharma
Medicon Village, Scheeletorget 1, Lund, Sweden
Patents
Products
Inhaled respiratory drug candidate (lead preclinical program)
Lead respiratory compound series candidate in preclinical development intended as an inhaled treatment for COPD and severe asthma demonstrating bronchodilatory and anti-inflammatory activity in preclinical assays.
PET imaging tracer project for cardiovascular diagnostics
Compound series developed for use in PET imaging to facilitate diagnosis of certain cardiovascular diseases; project currently not under active development.
Inhaled respiratory drug candidate (lead preclinical program)
Lead respiratory compound series candidate in preclinical development intended as an inhaled treatment for COPD and severe asthma demonstrating bronchodilatory and anti-inflammatory activity in preclinical assays.
PET imaging tracer project for cardiovascular diagnostics
Compound series developed for use in PET imaging to facilitate diagnosis of certain cardiovascular diseases; project currently not under active development.
Services
Pursues strategic collaborations and license agreements where external partners assume financial and operational responsibility for later-stage clinical development, manufacturing and commercialization of development candidates.
Pursues strategic collaborations and license agreements where external partners assume financial and operational responsibility for later-stage clinical development, manufacturing and commercialization of development candidates.
Expertise Areas
- Respiratory drug discovery and preclinical development
- Preclinical pharmacology and toxicology
- Phase I clinical preparation
- PET imaging agent development for diagnostics
Key Technologies
- Inhaled drug delivery (small molecules)
- Bronchodilatory small-molecule compounds
- Anti-inflammatory small-molecule compounds
- PET imaging tracers
News & Updates
Lundabolaget Arcede Pharma is preparing for phase I studies of the drug candidate RCD405, with strategic updates and management changes discussed in recent news.
Arcede Pharma is preparing for the redemption of warrants (TO1) with investor presentations and updates on the company's development.
The company is preparing for phase I clinical trials of RCD405, with updates on the progress and management.
Recent investor day presentation at Stockholm Stock Market highlighting company progress.
CEO Mia Lundblad presented the company at the BioStock Life Science Summit in October 2023.
Management changes and preparations for phase I studies of RCD405.
Lundabolaget Arcede Pharma is preparing for phase I studies of the drug candidate RCD405, with strategic updates and management changes discussed in recent news.
Arcede Pharma is preparing for the redemption of warrants (TO1) with investor presentations and updates on the company's development.
The company is preparing for phase I clinical trials of RCD405, with updates on the progress and management.
Recent investor day presentation at Stockholm Stock Market highlighting company progress.
CEO Mia Lundblad presented the company at the BioStock Life Science Summit in October 2023.
Management changes and preparations for phase I studies of RCD405.